Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.63 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.63 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.63 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.59 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.54 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824589 | 1.00 | ENPP2 (0.66) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL11306410 | 1.00 | ENPP2 (0.66) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL28066734 | 0.89 | ENPP2 (0.54) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL8824568 | 0.86 | S1PR1 (0.55) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL641483 | 0.83 | SMN1; SMN2 (0.57) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL8824565 | 0.83 | NR5A1 (0.51) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL11041654 | 0.83 | NR5A1 (0.51) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL915764 | 0.81 | ENPP2 (0.45) | ENPP2S1PR1S1PR3S1PR2LPAR2 | |
| SCHEMBL16301967 | 0.81 | NQO1 (0.54) | ENPP2TSHR | |
| SCHEMBL28066732 | 0.81 | S1PR1 (0.50) | ENPP2S1PR1S1PR3S1PR2LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190650-A1 | Inhibitors of Autotaxin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | US | claimed |
| WO-2012100018-A1 | INHIBITORS OF AUTOTAXIN | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | WO | claimed |
| US-8673882-B2 | Inhibitors of autotaxin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120190650-A1 | Inhibitors of Autotaxin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100018-A1 | INHIBITORS OF AUTOTAXIN | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190650-A1 | Inhibitors of Autotaxin | ENPP2, PHPT1, PSPH | ENPP2 1/4885S1PR1 2810/4885S1PR3 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.